April 06, 2016
Zecotek Receives First Patent for New Advanced Formulation of its Worldwide Patented LFS Scintillation Crystals
Singapore, April 6, 2016 – Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I.F, OTCPK: ZMSPF), a developer of leading-edge photonics technologies for industrial, healthcare and scientific markets, is pleased to announce that its wholly owned division, Zecotek Imaging Systems Pte. Ltd., has been granted its first patent in a series of pending patents for its advanced formulation of its patented LFS scintillation crystals. The patent is for multi-doped lutetium oxide based scintillators having improved photonic properties.
“This patent protects our latest version of LFS scintillation crystals which are the fastest, brightest and most advanced scintillation crystals available to any OEM worldwide: the LFS-M,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “Most crystals for high resolution positron emission tomography (PET) imaging are based on stoichiometric formulations of lutetium oxide with silicate. While we also use lutetium oxide with silicate, our team of Russian scientists use an off-stoichiometric process which produces superior scintillators. No other company can produce crystal like ours, and no other crystal can compete with the LFS-M’s speed and brightness. We have filed similar patent applications in important jurisdictions around the world to re-enforce and strengthen the existing patent for our line of LFS scintillation crystals.”
The new patent protects Zecotek’s latest and most advanced formulations of “off-stoichiometric” multi-doped lutetium oxide based scintillation silicate crystals (LFS-M). Stoichiometric formulations are known to have matching number of reactants which produce full conversion of reactive groups into highly definable cross-linked products. However, intentional deviation from stoichiometric formulations, off-stoichiometric, enable the creation of products containing predictable amounts of other residual reactive groups which in turn enables the tuning of mechanical properties. By going off-stoichiometric, Zecotek’s scientific team has produced the fastest, brightest and most advanced LFS formulation available today.
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances, the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
For Additional Information Please Contact:
Zecotek Photonics Inc.
T: (604) 783-8291
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.